Study compares Mounjaro to Wegovy for weight loss

Press/Media: Expert Comment

Description

A new clinical trial, sponsored by the manufacturer, found Mounjaro led to greater weight loss, but GPs warn of its ‘risks of biases’.

Subject

Obesity treatments

General practice

 

Period5 Dec 2024

Media contributions

1

Media contributions

  • TitleStudy compares Mounjaro to Wegovy for weight loss
    Degree of recognitionNational
    Media name/outletNewsGP
    Media typeWeb
    Country/TerritoryAustralia
    Date5/12/24
    DescriptionA new clinical trial, sponsored by the manufacturer, found Mounjaro led to greater weight loss, but GPs warn of its ‘risks of biases’...
    Chair of the REC–QC Professor Mark Morgan described the trial as ‘open-label and therefore subject to potential biases’.

    The research’s release comes after a separate, much larger-scale cohort study of 41,000 people investigated differences in weight loss between patients receiving tirzepatide compared with semaglutide.

    ‘In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide,’ the study concluded.

    ‘Future study is needed to understand differences in other important outcomes.’

    But in this study too, Professor Morgan said ‘detail was lacking about safety and side effects’.
    Producer/AuthorDr Manisha Fernando
    URLhttps://www1.racgp.org.au/newsgp/clinical/study-compares-mounjaro-to-wegovy-for-weight-loss?utm_source=racgpnewsgpnewsletter&utm_campaign=newsgpedm&utm_medium=email
    PersonsMark Morgan